Noile-Immune Biotech Inc

The company maintains a strong liquidity position, with a current ratio of 52.91 and cash and equivalents amounting to ¥5,240,477,000, which significantly exceeds its total liabilities of ¥107,217,000. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce its financial stability. The price-to-book ratio of 1.05 and price-to-tangible-book ratio of 1.05 suggest that the company is trading at a valuation close to its book value.

Profitability metrics indicate significant challenges, with a return on equity (ROE) of -6.36% and a return on assets (ROA) of -6.23%. The company reported a net loss of ¥340,176,000 and an operating loss of ¥339,285,000, reflecting ongoing operational inefficiencies and high R&D costs typical in the biotechnology sector. Gross profit of ¥2,392,000 is minimal compared to the company's revenue of ¥2,587,000, highlighting the need for cost optimization or revenue diversification.

The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of geographic diversification could pose a risk if the company's operations are heavily concentrated in a single market. The absence of segment-specific data limits the ability to evaluate the performance of individual business lines.

Looking ahead, the company is expected to continue facing financial challenges, as indicated by the negative net income and operating income. The analyst price target of ¥440.00 suggests a potential for significant upside, but this is based on a single strong-buy recommendation, with no additional buy or hold ratings. The company's growth trajectory remains uncertain, and its ability to achieve profitability will depend on successful R&D outcomes and commercialization of its products.

The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's strong cash position and absence of long-term debt reduce the likelihood of near-term financial distress. However, the high price-to-revenue ratio of 150.27 and negative EV/EBITDA of -1.15 suggest that the company is not currently generating sufficient earnings to justify its valuation. Investors should monitor the company's progress in R&D and its ability to achieve commercial milestones.

Recent events, including analyst estimates and price targets, indicate a positive outlook from a single analyst, but the lack of additional support from other analysts suggests a cautious approach. The company's financial performance and strategic direction will be critical in determining its future success. Investors should closely follow the company's quarterly reports and any updates on its R&D pipeline.

Analysts project 282.6% upside to a consensus target price of 440 JPY, reflecting strong buy sentiment.

The company maintains zero long-term debt, resulting in a debt-to-equity ratio of 0.0 and minimal leverage risk.

Revenue grew 521.2% year-over-year from FY-4 to FY-3, demonstrating significant top-line expansion momentum.

Dilution and liquidity risks are assessed as low, suggesting stable capital structure and market trading conditions.

Net margin of -131.49% places the company in the bottom quartile of its biotechnology cohort peers.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing financing.

Operating margin of -131.15% is significantly worse than the cohort median of -2.56%, indicating severe operational inefficiency.

Revenue collapsed to 5 million JPY in FY2026, down from 316.8 million JPY in FY2024, showing extreme volatility.

Free cash flow remains deeply negative at -793.5 million JPY in FY2026, requiring continuous external capital infusion.

Revenue ¥5.0M, −34,1% YoY; Operating income +25,4% YoY.

• ▍Revenue ¥5.0M, −34,1% YoY
• ▍Operating income +25,4% YoY
• ▍Net income +17,7% YoY
• ▍Free cash flow +17,7% YoY
• ▍Net margin -15870.7%

Revenue ¥7.6M, −97,6% YoY; Operating income −37,9% YoY.

• ▍Revenue ¥7.6M, −97,6% YoY
• ▍Operating income −37,9% YoY
• ▍Net income +14,7% YoY
• ▍Free cash flow +14,7% YoY
• ▍Net margin -12711.9%

Revenue ¥316.8M, −49,4% YoY; Operating income −629,1% YoY.

• ▍Revenue ¥316.8M, −49,4% YoY
• ▍Operating income −629,1% YoY
• ▍Net income −192,3% YoY
• ▍Free cash flow −192,3% YoY
• ▍Net margin -356.7%